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Abstract  
Background 
Heparan sulfate (HS) is present on the surface of virtually all mammalian cells and is 
a major component of the extracellular matrix (ECM), where it plays a pivotal role in 
cell-cell and cell-matrix cross-talk through its large interactome. Disruption of HS 
biosynthesis in mice results in neonatal death as a consequence of malformed lungs, 
indicating that HS is crucial for airway morphogenesis. Neonatal mortality (~50%) in 
newborns with congenital diaphragmatic hernia (CDH) is principally associated with 
lung hypoplasia and pulmonary hypertension. Given the importance of HS for lung 
morphogenesis, we investigated developmental changes in HS structure in normal and 
hypoplastic lungs using the nitrofen rat model of CDH and semi-synthetic 
bacteriophage (‘phage) display antibodies, which identify distinct HS structures. 
Results 
The pulmonary pattern of elaborated HS structures is developmentally regulated.  For 
example, the HS4E4V epitope is highly expressed in sub-epithelial mesenchyme of 
E15.5 – E17.5 lungs and at a lower level in more distal mesenchyme. However, by 
E19.5, this epitope is expressed similarly throughout the lung mesenchyme.  
We also reveal abnormalities in HS fine structure and spatiotemporal distribution of 
HS epitopes in hypoplastic CDH lungs. These changes involve structures recognised 
by key growth factors, FGF2 and FGF9. For example, the EV3C3V epitope, which 
was abnormally distributed in the mesenchyme of hypoplastic lungs, is recognised by 
FGF2. 
Conclusions 
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The observed spatiotemporal changes in HS structure during normal lung 
development will likely reflect altered activities of many HS-binding proteins 
regulating lung morphogenesis. Abnormalities in HS structure and distribution in 
hypoplastic lungs can be expected to perturb HS:protein interactions, ECM 
microenvironments and crucial epithelial-mesenchyme communication, which may 
contribute to lung dysmorphogenesis. Indeed, a number of epitopes correlate with 
structures recognised by FGFs, suggesting a functional consequence of the observed 
changes in HS in these lungs. These results identify a novel, significant molecular 
defect in hypoplastic lungs and reveals HS as a potential contributor to hypoplastic 
lung development in CDH. Finally, these results afford the prospect that HS-mimetic 
therapeutics could repair defective signalling in hypoplastic lungs, improve lung 
growth, and reduce CDH mortality. 
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Background  
The majority of the extracellular proteins involved in regulating embryonic 
development interact with heparin/heparan sulfate (HS), and, moreover, require HS 
for their cellular activities [1]. These include proteins required for lung 
morphogenesis [2-3]. For example, not only are fibroblast growth factors (FGFs) 
essential for lung development [4-10], but they require HS for FGF receptor 
activation and subsequent signalling [11-13]. Due to its vast interactome and location 
at the cell surface and within the extracellular matrix (ECM), HS is ideally positioned 
to integrate biochemical regulators of lung development with mechanical stimuli 
required for normal lung growth [14-15]. 
HS is a linear polysaccharide consisting of N-acetyl glucosamine-glucuronic acid 
disaccharide repeats. Chains are variably modified by N-deacetylation/N-sulfation of 
N-acetyl glucosamines, O-sulfation at various positions and conversion of glucuronic 
acid to its C-5 epimer, iduronic acid. These modifications do not occur at every 
potential site within a chain, resulting in a diverse range of HS chain structures 
displayed by a cell [1]. Moreover, HS is post-synthetically remodelled by 6-O-
endosulfatase enzymes, which selectively remove sulphate groups [16-18]. HS chains 
are usually attached to core proteins to form HS proteoglycans (HSPGs), which are 
expressed by most mammalian cells and represent a major component of the cell 
surface and ECM. Individual cells of a tissue display a variety of HS chains, which, in 
addition to being structurally complex and diverse, are dynamic, altering over time 
and with cellular physiology [3]. Since interactions between HS and proteins are 
mediated by specific HS structures, changes in HS structure in vivo are likely to alter 
HS:protein binding events and related signalling. Characterising HS fine structure in 
vivo is, therefore, important as it equates to a view of HS function.  
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Obtaining structural information on native HS is challenging due to the non-template 
nature of HS biosynthesis (unlike proteins or nucleic acids). Tissue HS is typically 
analysed by extraction and purification. However, the inherent averaging of this 
approach limits the information to an overall assessment of the mixed population of 
HS structures present, and all spatial information is lost. In addition, due to the 
relative low immunogenicity of HS, only a limited number of HS specific monoclonal 
antibodies are available [19-21]. However, single chain variable fragment (scFv) 
antibodies generated by bacteriophage (‘phage) display methodology [22-23] allow 
specific classes of structures in HS to be probed in situ. We have demonstrated 
recently that these antibodies display distinct specificities for different HS structures 
in vitro and, therefore, the individual HS epitopes they recognise, though structurally 
complex, are unique [24]. Limited analysis of one antibody shows that these probes 
are suitable to identify the diversity of HS in different cellular compartments of fetal 
lungs [25].  
HS plays a fundamental role in airway morphogenesis. In Drosophila and mice, 
disrupted HS biosynthesis in vivo results in defective airway branching, which in the 
mouse, results in lethal neonatal respiratory insufficiency [26-29]. In addition, 
digestion of endogenous HS in cultured lung explants using heparitinases or inhibition 
of HS sulfation with sodium chlorate, disrupts branching [30-31]. Further compelling 
evidence for a critical role of HS in lung disease is the association in humans and 
mice of mutations in the HSPG, glypican-3, with lung hypoplasia and congenital 
diaphragmatic hernia (CDH), known as Simpson-Golabi-Behmel syndrome [32-35]. It 
is, therefore, clear that HS is crucial for lung development and identifies HS as a 
potential contributor to pulmonary pathologies such as pulmonary hypoplasia in CDH 
[3]. 
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CDH is characterised by a diaphragmatic defect, herniation of abdominal contents 
into the thoracic cavity and pulmonary hypoplasia. The high neonatal morbidity and 
mortality is largely attributed to severe respiratory insufficiency resulting from 
hypoplastic lung growth and pulmonary hypertension. Hitherto, most work exploring 
the pathogenesis of human birth defects has focussed on the identification of changes 
in gene expression and/or in protein levels.  However, very few truly genetic causes of 
these defects have been identified. Since strong evidence supports a central role for 
HS as a master regulator of extracellular proteins controlling embryogenesis, we have 
investigated HS structure during development of the lung, and in the pathogenesis of 
CDH and pulmonary hypoplasia using HS specific ‘phage display antibodies. We 
utilised the teratogen-induced rodent model of CDH, which uses nitrofen (2,4-
dichlorophenyl-p-nitrophenyl ether) to induce congenital malformations in the 
offspring of treated pregnant dams with striking similarity to human CDH [36-38]. 
Here, we demonstrate that HS undergoes structural alterations during normal lung 
development and that there are pronounced abnormalities of HS structure and epitope 
distribution in hypoplastic lungs. Aberrations in epithelial basement membrane 
structure and composition were also identified in hypoplastic lungs, reflecting a 
specific abnormality in the ECM. The functional importance of these changes to HS 
structure during normal development and in hypoplastic lung is illustrated by our 
finding that a number of the HS epitopes are analogous to structures recognised by the 
critical morphogenetic growth factors, FGF2 and FGF9. Hence, these novel 
glycobiological defects may contribute to defective lung morphogenesis via altered 
interactions between HS and key signalling molecules such as FGFs. In addition, 
altered contacts between the ECM and cell surface are likely to interrupt 
mechanotransduction across a tissue, which is crucial for morphogenesis. HS may, 
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therefore, play significant biochemical and biomechanical roles in the pathogenesis of 
pulmonary hypoplasia in CDH. 
 
Results  
Seven HS ‘phage display antibodies were chosen on the basis that they have been 
raised against HS/heparin from a variety of tissue sources and display distinct binding 
specificities, which we have characterised in depth [24]. The data on antibody binding 
specificities and epitope structures are summarised in Table 1. 
 
Table 1. Binding specificities of HS antibodies and characteristics of the recognised 
epitopes, extracted from [24]. 
Antibody Sulfation preference Disulfated preference 
Binds 
monosulfated? 
Oligosaccharide 
length required 
for significant 
binding 
 
HS3B7V 
 
Hep > 2S,NS > 6S,NS > HS > 
6S,2S > 6S > 2S 
2S, NS or 
6S, NS 2S or 6S >dp10 
 
HS4E4V 
 
HS > 6S,NS = 2S,NS > Hep >  
6S > 6S,2S 
2S, NS or 
6S, NS Only 6S dp8 
 
HS3A8V 
 
Hep > 2S,NS = HS > 6S,NS >  
6S > 6S,2S 2S, NS Only 6S dp6 
 
AO4B08V 
 
Hep > HS > 2S,NS > 6S >  
NS,6S > 6S,2S > 2S 2S, NS 2S or 6S dp4 
 
EV3C3V 
 
Hep > 2S,NS > HS > 6S,NS > 
6S,2S ≥ 6S 2S, NS Only 6S dp8 
 
EW4G1V 
 
Hep > 2S,NS > HS > 6S,NS ≥ 
6S,2S = 6S > 2S 2S, NS 2S or 6S dp8 
 
(dp) degree of polymerisation, i.e., a disaccharide is a dp2, tetrasaccharide a dp4, etc. 
(Hep) heparin, (HS) heparan sulfate, (NS) N-sulfate, (2S) 2-O-sulfate, (6S) 6-O-
sulfate,  
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HS structure changes during normal rat lung development 
Different staining patterns were observed in developing rat lung with the various HS 
antibodies, indicating recognition of distinct HS epitope structures (Figure 1 and 
Table 2).  
 
Table 2. Summary of the spatiotemporal distribution of HS epitopes in normal and 
nitrofen-treated hypoplastic fetal lungs. 
E13.5 E15.5 E17.5 E19.5 E21.5 
 
Cont Nitr Cont Nitr Cont Nitr Cont Nitr Cont Nitr 
HS3B7V           
Epithelium - n/a - - - - - - - - 
BM - n/a +++ ++ +++ ++ +++ ++ ++ + 
Mesenchyme;           
     Sub-epithelial 
     Sub-mesothelial 
- 
- 
n/a 
n/a 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
+ 
- 
+ 
+ 
+ 
+ 
HS4E4V      
Epithelium - n/a - - - - - - - - 
BM +++ n/a +++ + +++ ++ +++ ++ ++ ++ 
Mesenchyme;           
     Sub-epithelial 
     Sub-mesothelial 
+ 
- 
n/a 
n/a 
+++ 
+ 
+/- 
- 
++ 
+ 
+ 
- 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
HS3A8V      
Epithelium - n/a ++ - + - - - - - 
BM +++ n/a +++ ++ +++ ++ +++ ++ +++ ++ 
Mesenchyme;           
     Sub-epithelial 
     Sub-mesothelial 
- 
- 
n/a 
n/a 
+++ 
++ 
++ 
++ 
+++ 
+ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
AO4B08V      
Epithelium - n/a ++ + + - - - - - 
BM + n/a +++ + +++ + +++ - ++ + 
Mesenchyme;           
     Sub-epithelial 
     Sub-mesothelial 
- 
- 
n/a 
n/a 
- 
- 
+ 
+ 
++ 
+ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
EV3C3V      
Epithelium ++ n/a ++ - + - - - - - 
BM +++ n/a +++ ++ +++ ++ +++ ++ +++ ++ 
Mesenchyme;           
     Sub-epithelial 
     Sub-mesothelial 
+ 
+ 
n/a 
n/a 
+++ 
+ 
++ 
++ 
+++ 
+ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
++ 
++ 
++ 
++ 
EW4G1V      
Epithelium - n/a + - - - - - - - 
BM - n/a +++ + +++ ++ +++ ++ +++ ++ 
Mesenchyme;           
     Sub-epithelial 
     Sub-mesothelial 
- 
- 
n/a 
n/a 
+ 
- 
+ 
- 
+ 
- 
+ 
- 
++ 
++ 
+++ 
++ 
++ 
++ 
++ 
++ 
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Levels of immunostaining in the various lung compartments were scored blind by two 
independent observers with images that were representative of three separate lung 
samples, as follows: -  
-  no staining,    +/-  very low staining,    +  low staining,    ++  moderate staining,   
+++  high staining 
 
One particular HS epitope recognised by HS4C3V was not identified in developing 
rat lungs of any age. The use of adult rat kidney as a positive control demonstrates 
that this structure is indeed absent from lung (Figure 1). The remaining six antibodies 
show distinct patterns of staining in fetal rat lungs, and the various lung compartments 
display different HS structures (additional files 1, 2, 3, 4, 5 and 6, summarised in 
Table 2). For example, in airway epithelium, HS structures recognised by EV3C3V, 
AO4B08V and HS3A8V are displayed, whereas the other three antibody epitopes are 
not.  At E13.5, only the EV3C3V HS epitope is displayed by the epithelium, and at 
E15.5, the AO4B08V and HS3A8V HS epitopes are also present (Figure 2). The 
spatial localisation of these HS epitopes was shown to change during lung 
morphogenesis, indicating alterations in the structure of native HS chains during 
mammalian lung development (Figures 1 and 3 and additional files 1, 2, 3, 4, 5 and 
6). For example, the HS epitope recognised by HS3A8V is displayed exclusively by 
epithelial basement membranes at E13.5 at a high level. At the early pseudoglandular 
period (E15.5), this structure is additionally displayed at a high level throughout the 
mesenchyme and by the airway epithelium. At the late pseudoglandular period 
(E17.5), mesenchymal expression of this epitope remains high; however, distribution 
of the structure becomes particularly concentrated around smaller developing airways 
and epithelial staining is no longer present. At canalicular (E19.5) and saccular 
(E21.5) fetal stages, HS3A8V epitope levels in the mesenchyme decrease and epitope 
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distribution becomes more widespread (Figure 3 and Table 2). In contrast, the HS 
epitope identified by EW4G1V is not present in E13.5 rat lungs; however, at E15.5 it 
is detected in epithelial basement membranes and in the surrounding mesenchyme at a 
low level (Figure 3 and Table 2). At E17.5, levels of this HS epitope drastically 
increase, particularly in epithelial basement membranes, while epitope levels in the 
mesenchyme remain low and its distribution becomes concentrated around smaller 
distal airways. From E19.5 – E21.5, distribution of the EW4G1V epitope becomes 
more widespread throughout the mesenchyme (Figure 3 and Table 2). 
In the pulmonary vasculature, HS3B7V shows a unique staining profile, specifically 
highlighting regions in the outer tunica media of arterial walls (Figure 4). This HS 
structure is absent from the inner medial layer, in contrast to the other five antibody 
epitopes, which were present and showed comparable vascular staining, highlighting 
the medial layer of both arteries and veins, predominantly the basal lamina 
surrounding smooth muscle cell layers (Figure 4). 
 
HS structure is abnormal in hypoplastic lungs from nitrofen-induced CDH 
Identification of HSPGs with the 3G10 antibody, which recognises the neo-epitope 
generated on all HSPGs following heparitinase digestion of the HS chains, indicated 
that there is no gross disruption in the overall spatial localisation of HSPGs in 
hypoplastic lungs. However, levels of HSPGs are reduced, particularly at E15.5 – 
E17.5 and in epithelial basement membranes (Figure 5A). Analysis of specific HS 
epitopes with ‘phage display antibodies indicated an abnormality in the fine structure 
of HS in hypoplastic lungs, which was also more marked in lungs of earlier gestation 
(Figures 5, 6 and 7, summarised in Table 2). Levels of a number of HS epitopes are 
reduced (AO4B08V) or lost (HS3A8V, EV3C3V and EW4G1V) from the airway 
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epithelium at E15.5 and E17.5 compared to normal lungs (Figure 5B and Table 2). 
Moreover, all of the HS structures analysed are displayed at a lower level by epithelial 
basement membranes. Although a number of HS structures are also shown to be 
reduced in hypoplastic lung mesenchyme (HS4E4V, HS3A8V and AO4B08V at 
E15.5 – E17.5) (Figure 5C and additional files 2, 3 and 4), HS structural alterations 
are more complex than a simple reduction or loss of epitopes. Levels of the HS 
epitope identified by EV3C3V are increased in hypoplastic lung mesenchyme, and in 
addition, the spatial distribution of this HS structure is abnormal (Figure 6 and Table 
2). In E15.5 – E17.5 control lung mesenchyme, a gradient of EV3C3V epitope 
distribution is observed, with sub-epithelial areas adjacent to smaller, distal airways 
displaying high epitope levels and more proximal regions of the lung displaying a 
lower level of the structure. However, in nitrofen treated hypoplastic lungs, this 
gradient is not present and epitope distribution is more widespread throughout the 
entire lung mesenchyme (Figure 6 and Table 2). At E19.5 – E21.5, EV3C3V epitope 
levels and distribution are comparable to that observed in control lungs. 
Pulmonary arteries of nitrofen-treated hypoplastic lungs have thickened vessel walls 
with increased smooth muscle content, contributing to the persistent pulmonary 
hypertension associated with CDH [39-41]. Although we confirmed marked 
thickening in arterial walls of nitrofen-treated lungs, no difference in HS or HSPG 
staining was observed. All HS antibodies highlighted the tunica media, with five 
predominantly staining the basal lamina surrounding the layers of smooth muscle and 
HS3B7V specifically highlighting an outer region of the arterial walls.  
 
HS/HSPG staining identifies abnormalities in epithelial basement membranes 
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Abnormalities in epithelial basement membrane HSPG expression and HS structure 
were identified in hypoplastic lungs. Basement membranes appear thinner, and levels 
of both HSPGs (Figure 7A) and specific HS epitopes (Figure 7B and C) are reduced. 
In addition, staining with HS antibodies revealed discontinuities in basement 
membrane HS distribution, which are not observed with 3G10 
immunohistochemistry.  
To examine the general structure of epithelial basement membranes in hypoplastic 
lungs and evaluate whether abnormalities are HS/HSPG specific, hypoplastic rat 
lungs were probed with an antibody to laminin (Figure 7D), an integral component of 
basement membranes. Immunohistochemical detection of laminin indicated that 
epithelial basement membranes are indeed thinner; however, no discontinuities in 
laminin staining were observed (Figure 7D). The abnormally fine laminin staining of 
epithelial basement membranes was more pronounced in lungs at the pseudoglandular 
stages of development (E15.5 and E17.5), reminiscent of HS and HSPG basement 
membrane staining. 
 
Functional analysis of HS epitopes using ELISA 
To further our understanding of the functional consequences of abnormal HS structure 
identified in hypoplastic lungs, we analysed the specificities of the HS antibodies in 
competition ELISAs with FGF2 and FGF9, which are known to be involved in lung 
morphogenesis [4, 42-44]. The relative binding affinities of FGFs for HS epitopes 
were evaluated by determining IC50 values, defined as the concentration of FGF that 
inhibits antibody binding to HS by 50 % (Figure 8). This allowed us to investigate 
possible overlap between antibody epitope structures and FGF binding sites in HS, to 
identify potential biological functions of the antibody epitopes.  
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FGF2 competed for all six antibody epitopes to varying extents (Figure 8A and B), 
whereas FGF9 only competed for two antibody epitopes, recognised by HS3B7V and 
HS3A8V (Figure 8C and D). The ability of FGF2 to compete for HS3B7V, HS4E4V 
and HS3A8V epitopes was similar, with IC50 values of 150 nM ± 2.8 nM, 130 nM ± 
26 nM and 130 nM ± 1.9 nM. FGF2 also showed comparable competition for 
AO4B08V and EW4G1V epitopes, with IC50 values of 85 nM ± 4.2 nM and 94 nM ± 
7.1 nM. Significant competition for the EV3C3V epitope structure in HS was 
achieved with FGF2, with an IC50 value of 9.3 nM ± 2 nM. In contrast to FGF2, FGF9 
only competed with two antibodies, HS3B7V and HS3A8V, for HS binding, with IC50 
values of 670 nM ± 18 nM and 1.8 µM ± 0.81 µm, respectively (Figure 8C and D). 
 
Discussion and Conclusions 
HS is a master regulator of morphogenesis and is essential for lung development. In 
the present study, we have demonstrated spatiotemporal alterations in HS structure 
and distribution during normal and hypoplastic lung development using HS specific 
‘phage display antibodies. Moreover, we show that a number of antibody epitopes are 
also structures recognised by FGFs, suggesting that abnormal distribution of these 
epitopes in hypoplastic CDH lungs may alter FGF binding, with functional 
consequences for morphogenesis.  
 
HS structure in normal fetal rat lungs 
A number of HS scFv antibodies have been used previously to analyse HS structures 
in adult human lungs [45]. Only one of these antibodies used in the previous work is 
used in the present study (EV3C3V). In adult lungs, the EV3C3V HS epitope is 
identified in airway epithelial cells and their underlying basement membranes and in 
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basement membranes surrounding smooth muscle cells of blood vessels [45]. We also 
identified the EV3C3V epitope in epithelial and smooth muscle cell basement 
membranes at all developmental stages (Figures 2, 4, 6 and additional file 5) and in 
airway epithelial cells at E13.5 – E17.5 (Figure 2). This demonstrates a degree of 
conservation in HS structure between species.  
We demonstrate that distinct cellular compartments of the lung display a variety of 
HS chains of different structure, which are modified during lung development, with 
temporal variation in both expression level and spatial localisation of HS epitopes 
identified by HS antibodies.  
The epitope for one antibody, HS4C3V, was not identified in fetal lungs, however, it 
was present in kidney tissue (Figure 1) and has previously been detected in 
immunoblots of solubilised fetal lung extracts [24]. This raises the possibility of 
cryptic binding sites for the antibodies in situ, and is an important consideration when 
interpreting immunohistochemical data, i.e., the absence of an epitope in situ does not 
necessarily mean it is not present in a tissue, rather, the epitope may be masked, for 
example, by endogenous proteins bound to HS. The antibodies, therefore, specifically 
highlight free binding structures in HS. Indeed, occupied, cryptic binding sites in HS 
in situ have been identified previously in growing mammary glands probed with 
FGF2 [46].  
The antibody binding specificities (Table 1) suggests the nature of the observed 
changes in HS structure that occur in developing lungs. For example, the HS4E4V HS 
epitope is not found in E13.5 lungs, and at E15.5 – E17.5, the epitope is identified in 
the mesenchyme surrounding distal, but not proximal airways (Figure 1 and additional 
file 2). This can be explained by contrasting patterns of sulfation, e.g., highly sulfated 
HS modified with both 6-O- and 2-O-sulfates are located in the mesenchyme 
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surrounding proximal airways, while less sulfated HS, modified by 6-O- or 2-O- 
sulfates is found in mesenchyme surrounding distal airways, where it offers optimal 
binding  for HS4E4V  [24]. In contrast to HS4E4V, HS3A8V binds to more highly 
sulfated HS, particularly N-sulfated sequences (Table 1), and displays a wider epitope 
distribution throughout fetal lung mesenchyme (Figures 1 and 3). Hence, more highly 
sulfated HS in proximal mesenchyme may allow binding of HS3A8V, but not 
HS4E4V, while a more heterogeneous population of HS structures in distal 
mesenchyme, allows binding of both.  
The localisation of specific HS structures within the developing lung and their 
importance for the coordination of branching morphogenesis has been hinted at in 
previous studies, e.g., expression of the epitope recognised by the HS specific 
monoclonal antibody, 10E4, was shown to alter rapidly with lung growth in vitro [31]. 
In addition, blanket addition of heparin to lung cultures lacking endogenous sulfated 
GAGs after sodium chlorate treatment results in generalised epithelial expansion, 
indicating a global growth response, rather than defined branching [31]. These data, 
together with ours, suggest that distinct HS structures are specifically displayed by the 
various lung cell types to direct localised signalling and spatiotemporally restricted 
morphogenetic cues, e.g., epithelial budding. In addition, modification of HS fine 
structure during development, together with alterations in HS microenvironment via 
dynamic HS:protein interactions, will influence crucial cell-cell and cell-matrix 
communication governing lung morphogenesis. HS structural dynamics are, therefore, 
likely to be an important regulator of fetal lung morphogenesis.  
 
HS structure and epitope distribution are abnormal in hypoplastic CDH lungs  
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Using the nitrofen rat model of CDH, we investigated the potential role of HS in 
hypoplastic lung development, since HS has been shown to be crucial for normal lung 
morphogenesis. In addition, it has been shown previously that nitrofen-exposed rat 
lung explants respond abnormally to exogenous FGF1 and FGF2 and also heparin, 
suggesting a possible defect in the FGF:FGFR:HS signalling system [47-48]. Notably, 
in humans, a mutation in the gene encoding the HSPG, glypican-3, features multiple 
congenital anomalies, including CDH [32-35]. 
Following analysis of HS fine structure and its developmental regulation during 
normal rat lung morphogenesis, HS structure and distribution was analysed in 
hypoplastic lungs from rats with nitrofen-induced CDH. In hypoplastic lungs, HSPG 
expression is reduced, and in addition, specific abnormalities in HS structure and 
spatial distribution were observed, which cannot simply be a consequence of an 
overall reduction in the level of HSPGs, since the level of some epitopes is increased, 
e.g., EV3C3V (Figure 6). As the overall distribution of HSPGs appears the same in 
control and hypoplastic lungs, abnormalities in the spatial distribution of specific 
epitopes is likely to reflect alterations in HS fine structure and irregular localisation of 
discrete HS structures displayed by the various lung cell types. In addition, the 
occupancy or availability of antibody binding sites may differ in hypoplastic lungs 
due to differences in protein binding events. It is of note that the molecular 
abnormalities highlighted in hypoplastic lungs are most striking at the 
pseudoglandular period of respiratory morphogenesis, when the lung is actively 
branching (E15.5 – E17.5) (Figures 5 and 6 and additional files 1, 2, 3, 4, 5 and 6). 
This supports previous work, suggesting that in CDH, lungs are intrinsically abnormal 
from early stages of organogenesis and that lung defects emerge in tandem alongside 
the hernia [49-51].  
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Abnormal HS structure has been shown to result in defective lung development in 
previous studies, e.g., in mice lacking HS biosynthetic enzymes, NDST-1 or C5-
epimerase [27-28]. In Drosophila, RNAi of HS 6-O-sulfotransferase (HS6ST) 
perturbs FGF signalling and disrupts primary branching of the tracheal system [52] 
and, similarly, a proportion of mutant Drosophila embryos lacking functional HS6ST 
develop tracheal branching defects [53]. The generation of double mutants lacking 
functional 2-O-sulfotransferase (HS2ST) and HS6ST is completely lethal, with 
disrupted FGF signalling and a failure of tracheal precursor cells to migrate to form 
primary branches [53]. In the mammalian lung, chemical inhibition of HS sulfation 
prevents FGF10 induced epithelial budding [30] and HS6ST1 deficient mice exhibit 
impaired alveolarisation [54]. In contrast to previous studies where HS biosynthesis 
has been perturbed and effects on the lung sought, the present study investigates an 
established developmental malformation (pulmonary hypoplasia, CDH) to show for 
the first time that hypoplastic lungs feature substantial abnormalities of HS structure 
and epitope distribution. Moreover, previous studies in which HS has been disrupted, 
e.g., by deletion of genes encoding HS biosynthetic enzymes, have not characterised 
in any depth the actual effects on HS structure and epitope distribution in the 
malformed lung.  
Changes in HS structure in the lung is likely to modify HS:protein interactions, since 
these rely on specific HS structures [1]. This in turn, will affect various signalling 
systems, as HS:protein interactions have been shown to be functionally significant, 
regulating transport and effector functions of the protein ligand. For example, HS 
plays a key role in FGF signalling, which is fundamental for lung morphogenesis.  
HS facilitates interactions between FGFs and FGFRs and is also required for 
sustained FGFR activation and subsequent cellular signalling [11-13]. Cells 
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expressing FGFRs but lacking HSPGs are unresponsive to FGF unless heparin/HS is 
added [11-12] and treatment of cells with sodium chlorate or heparinase blocks the 
biological activity of FGFs, an effect which can be restored by the addition of 
exogenous heparin [13]. In an ex vivo model system of epithelial branching 
morphogenesis using mouse salivary gland, modification of FGF:HS binding 
affinities was shown to impact upon the morphogenetic effect of FGFs [55]. FGF10 
with a reduced affinity for HS (via single amino acid mutations in the heparin binding 
site), formed abnormal gradients due to altered transport properties, resulting in an 
induction of epithelial branching rather than elongation observed with wild type 
FGF10 [55]. In contrast, reduced affinity of FGF10 for its receptor, FGFR2b, affected 
only the extent of the response, without altering the nature of the response.  
Abnormal HS structure and distribution observed here in hypoplastic lungs can, 
therefore, be expected to contribute to defective lung morphogenesis via aberrant 
epithelial-mesenchymal signalling as a result of altered HS:protein interactions.  
 
Competitive selectivity of FGFs and antibodies provides insight into 
structure:function relationships of epitopes and a functional consequence of 
abnormal HS in hypoplastic lungs  
Competitive binding assays with FGFs and HS antibodies allowed us to demonstrate 
that antibodies recognise specific HS structures that are also recognised by key FGF 
morphogens, thereby revealing biological relevance of epitopes. Alterations in FGF 
bindings sites in the lung has previously been shown to have functional consequences 
for morphogenesis [30]. 
FGF2 is expressed in the developing lung and is important for lung morphogenesis 
[43-44, 56]. The HS binding specificity of FGF2 is well characterised, requiring N-
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sulfated and 2-O-sulfated HS structures [57-58] and at least a tetrasaccharide [59] for 
binding. In competitive binding assays, FGF2 competed with all six HS antibodies to 
varying extents. Of particular note is the effectiveness of FGF2 to compete with 
EV3C3V, which was significantly higher compared to competition with the other 
antibodies (Figure 8A and B). Previous characterisation of epitope structures reveals 
that EV3C3V binding structures are analogous to those recognised by FGF2. Both 
require N-sulfation and 2-O-sulfation for binding, with little sensitivity to the 
presence or absence of 6-O-sulfates (Table 1) [24, 57]. The other epitopes appear to 
overlap in part with structures recognised by FGF2, requiring a higher concentration 
of FGF2 to successfully compete with the antibodies. These structures may represent 
lower affinity binding sites for FGF2, which have been previously identified in HS 
[60].   
Similarly, FGF9 is essential for normal lung development [4, 42, 61-62]. In binding 
assays, FGF9 showed more selective competition than FGF2, competing only for the 
epitopes recognised by HS3B7V and HS3A8V (Figure 8C and D). Although the 
binding specificity of FGF9 is not as well characterised as that of FGF2, the 
competitive binding data for FGF9 illustrates the biological relevance of the observed 
variation in these epitopes in normal and hypoplastic prenatal lungs. FGF9 competes 
most effectively for HS3B7V epitopes, with an IC50 value almost three times lower 
than with HS3A8V (670 nM compared to 1.8 µM). We have previously shown that 
HS3B7V requires longer HS structures for significant binding (Table 1) [24], and this 
may also reflect the binding specificity of FGF9. As FGF9 has been shown to readily 
form homodimers in solution [63-64], the requirement for longer HS structures for 
binding may not be that surprising. 
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Functional analysis of epitope structures enables us to suggest potential biological 
consequences of abnormal epitope distribution in developing lungs. In CDH 
hypoplastic lungs, the EV3C3V epitope was identified at a higher level compared to 
normal lungs, and in addition, was shown to be abnormally distributed in hypoplastic 
lung mesenchyme (Figure 6). This may indicate an increase in the number of 
EV3C3V epitopes and, therefore, structures recognised by FGF2, in the HS 
synthesised by the lung cells. Alternatively, the availability of these structures may be 
increased in the lung mesenchyme due to altered expression of proteins that bind this 
class of structures. Moreover, these lungs respond abnormally to FGF2 [47]. Addition 
of FGF2 to nitrofen-treated lung explants results in increased lung area and formation 
of dilated, cystic airways, whereas FGF2 was shown to have minimal effect on the 
growth of control lung explants [47]. Our data describing an increased number of 
available EV3C3V/FGF2 binding structures in the mesenchyme of hypoplastic lungs 
provides a possible explanation for this abnormal response to exogenous FGF2.  
Epitopes analogous to structures recognised by FGF9, i.e., the HS3A8V and HS3B7V 
epitopes, were also abnormally expressed in nitrofen-treated lungs. Both epitopes 
were expressed at a reduced level in epithelial basement membranes and in addition, 
showed abnormal mesenchymal expression (Table 2 and additional files 1 and 3). The 
HS3B7V epitope was displayed at a low level in sub-epithelial mesenchymal 
compartments of E19.5 hypoplastic lungs, and this is a compartment which was not 
stained in normal lungs (Table 2 and additional file 1). The HS3A8V epitope was 
identified at a high level in sub-epithelial mesenchyme at E15.5 and E17.5 in normal 
lungs, however, in hypoplastic lungs, mesenchymal expression was reduced and the 
partitioning of HS3A8V staining in sub-epithelial and sub-mesothelial mesenchyme 
was not evident (Table 2 and additional file 3). Thus, these HS structures recognised 
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by FGF9 are either synthesised at an abnormal frequency in HS chains, or the 
availability of these structures in HS chains is reduced in an irregular manner. FGF9 
has been shown to be particularly important for mesenchymal growth and 
differentiation [4, 42, 62, 65] and mesenchymal-epithelial signalling through 
regulation of other morphogen expression levels [62]. An abnormal distribution of HS 
structures able to bind FGF9 in the lung mesenchyme may, therefore, have a 
significant effect on FGF9 transport between cellular compartments and/or activity, 
including downstream effects on other morphogens regulated by FGF9, for example, 
SHH and FGF7 and FGF10 [42, 62].  Collectively, these data suggest that observed 
changes in HS structure in hypoplastic lungs is likely to result in altered interactions 
with critical regulatory proteins, such as FGFs, leading to irregular cell signalling and 
epithelial-mesenchymal cross-talk, which may ultimately contribute to defective lung 
morphogenesis.  
 
Abnormal HS may help explain disrupted mechanobiology in hypoplastic lungs 
The ECM facilitates communication between cellular and extracellular environments, 
including mechanotransduction [66-68]. Prenatal airway smooth muscle (ASM) 
exhibits periodic contractility resulting in rhythmic airway peristalsis, which moves 
lung liquid along the airways and induces a distending pressure in end buds, 
stretching the lung to promote growth [69-72]. Demonstrating a specific link between 
HS dependent signalling and airway contractility, FGF10 is synthesised by these 
ASM cells [73] and stimulates airway peristalsis [70]. However, in hypoplastic lungs 
from the nitrofen CDH model, reduced FGF10 levels [74] accompany abnormal 
airway peristalsis [75-76]. Given the large HS interactome, the structural changes in 
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HS identified here provide a promising possible explanation for the mechanical 
abnormalities measured in hypoplastic lungs.  
 
Epithelial basement membranes are abnormal in hypoplastic lungs 
Basement membranes are specialised extracellular matrices underlying epithelial and 
endothelial cells [77] composed mainly of collagen IV, laminin, nidogen/entactin and 
proteoglycans including HSPGs, perlecan [78], agrin [79-80] and collagen XVIII [81-
82]. HSPGs contribute to basement membrane assembly, structure and function: e.g., 
when grown in sodium chlorate, murine teratocarcinoma cells develop an incorrectly 
assembled basement membrane [83]. In addition, heparin and HS influence 
associations between basement membrane components, laminin and collagen IV [84-
85]. HSPGs also regulate growth factor activity by controlling their transport through 
the matrix and sequestering them to form local reservoirs [86-89]. In the developing 
lung, basement membranes are pivotal for epithelial-mesenchymal cross talk and 
irregular assembly and structure of airway basement membranes is detrimental to lung 
morphogenesis [90-91]. 
We have shown here that hypoplastic lungs exhibit abnormal epithelial basement 
membranes. Immunodetection of laminin, HSPGs and HS structures demonstrated an 
abnormally thinned basement membrane. Additionally, HS epitopes, but not HSPGs 
or laminin, were displayed discontinuously in hypoplastic lungs, suggesting abnormal 
localisation of HS epitopes and/or availability of binding sites in HS. 
 
Clinical implications 
Current treatments for CDH primarily focus on postnatal management to address the 
consequences of pulmonary hypoplasia and hypertension, including strategies aimed 
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at providing adequate tissue oxygenation via inhaled nitric oxide, high frequency 
oscillatory ventilation and extracorporeal membrane oxygenation (ECMO). However, 
CDH mortality has not been greatly improved. Results from the present work suggest 
that heparin/HS based therapeutics may be beneficial in ameliorating hypoplastic lung 
growth in CDH. Indeed, a number of glycotherapeutics are emerging for the repair of 
damaged tissue, e.g., skin and bone [92-96] and for the treatment of some cancers [97-
99]. The morphogenetic effect of chemically modified heparins has previously been 
investigated in salivary gland branching morphogenesis [100]. Using a similar 
rationale, investigating the effect of various engineered heparins on lung growth may 
help develop a class of HS structures able to ameliorate lung hypoplasia, reduce 
smooth muscle cell proliferation and increase vascular branching.  With chemically 
modified heparins available, which possess low or zero anticoagulant activity [101], 
this is an exciting potential future therapeutic avenue. 
 
Methods 
Lung retrieval and induction of CDH 
Timed-pregnant Sprague-Dawley rats (Charles River, UK) were gavage fed 100 mg 
nitrofen (2,4-dichloro-4'-nitrodiphenylether) (Zheijang Chemicals, Hangzhou, China) 
dissolved in olive oil on day 9.5 of gestation (vaginal plug positive, day 0) to induce 
left-sided CDH and pulmonary hypoplasia in newborn pups [49]. Control animals 
received olive oil. Embryos and fetuses were harvested on embryonic day (E)13.5 
(controls only), E15.5, E17.5, E19.5 and E21.5 of gestation by caesarean section 
under terminal anaesthesia (intraperitoneal sodium pentobarbitone). Lungs were 
dissected out and fixed in 4% (w/v) paraformaldehyde in phosphate buffered saline 
(PBS) (7.5 mM Na2HPO4, 2.8 mM NaH2PO4, 150 mM NaCl pH 7.4). Lungs were 
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washed in PBS, cryoprotected with 20% (w/v) sucrose in PBS overnight and gelatine 
embedded. Gelatine blocks containing lung tissue were covered in Cryo-M-Bed 
(Bright, Huntington, UK) and snap frozen in cooled isopentane. Adult kidney was 
prepared in the same way. Tissue sections were cut at 8 µm on a cryostat, mounted 
onto chrome alum gel slides and stored at -40°C. 
All animal procedures complied with the UK Animal (Scientific Procedures) Act 
1986 and were conducted with UK Home Office approval, ref. PPL40/2293. 
 
Immunohistochemistry 
Slides were removed from - 40°C, allowed to thaw and rinsed in PBS. Sections were 
blocked in 10% (v/v) goat serum in PBS for 2 h at room temperature for all 
antibodies. Following immunohistochemistry, sections were mounted with fluorescent 
mounting medium. Scoring of staining was performed blind by two independent 
observers with images that were representative of at least three separate lung samples. 
HS ‘phage display scFv antibodies 
HS antibodies were diluted 1/5 in 1% (v/v) goat serum in PBS and incubated with 
lung sections overnight at 4°C. Bound antibody was detected with rabbit VSV-G tag 
antibody (Abcam, Cambridge, UK), diluted 1/200 in 1% (v/v) goat serum in PBS, for 
2 h at room temperature, followed by FITC conjugated goat anti-rabbit IgG (Sigma-
Aldrich, Gillingham, UK), diluted 1/500 in the dark for 1 h. Controls were the 
omission of HS antibody or treatment of sections with heparitinase (EC 4.2.2.8) 
(IBEX Technologies Inc, Canada) overnight at 37°C (changing enzyme after 4 h), 
prior to antibody incubation, to remove HS epitopes. 
HSPG specific antibody, 3G10 
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In order to reveal the 3G10 neo-epitope in tissue sections, endogenous HS was 
digested with heparitinase (EC 4.2.2.8) overnight at 37°C, replacing enzyme after 4 h. 
3G10 antibody (Seikagaku/AMS Biotechnology, Oxon, UK) was diluted 1/200 in 1% 
(v/v) goat serum in PBS and incubated with lung sections overnight at 4°C. Bound 
antibody was detected using FITC conjugated goat anti-mouse IgG (Sigma-Aldrich, 
Gillingham, UK), incubated in the dark for 1 h. Controls were omission of 3G10 
antibody or omission of heparitinase digestion to leave HS chains intact and the 3G10 
neo-epitope unavailable. 
Laminin antibody 
Rabbit anti-laminin (Sigma-Aldrich, Gillingham, UK) was diluted 1/100 in 1% (v/v) 
goat serum in PBS and sections incubated overnight at 4°C. Bound antibody was 
detected with FITC conjugated goat anti-rabbit IgG, diluted 1/200 and incubated in 
the dark for 1 h. 
 
FGF2 and FGF9 synthesis and purification 
Full-length human recombinant FGF2 with an N-terminal hexahistidine tag was 
produced in E. coli exactly as described [102]. FGF9 (Uniprot Accession: P31371; 
residues: 1-208) with a 6×Histidine tag and a TEV cleavage site (26 amino acids, 
MKHHHHHHPMSDYDIPTTENLYFQGA) at the N-terminus was expressed in C41 
E.coli cells using a modified pET-24b vector (pETM-11, kind gift from Dr Paul 
Elliott, University of Liverpool), which provides the sequences of the 6×Histidine tag 
and the TEV cleavage site. Protein was produced in bacteria using an auto induction 
system [103]. Cells were grown at 37°C, for 7 h in Terrific Broth, and FGF-9 
production was induced at 22°C for 16 h. Cell pellets were lysed by sonication in 
Buffer A9 (0.3 M NaCl, 50 mM Tris, 1 mM DTT, pH7.4) with 0.2 mg/ml lysozyme 
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(lysozyme, chicken egg white, Calbiochem, Nottingham, UK), 10 µg/ml DNase I 
(deoxyribonuclease I, from bovine pancreas, Sigma-Aldrich, Gillingham, UK), 1 
tablet of protease inhibitor (complete EDTA-Free, Protease Inhibitor Cocktail Tablets, 
Roche, West Sussex, UK), 0.2% (v/v) Tween-20 and 5% (v/v) glycerol. The lysate 
was loaded onto 5 ml heparin agarose column (Affi-Gel Heparin Gel, Bio-rad, Hemel 
Hempstead, UK), which was washed with Buffer A9 until the absorbance returned to 
baseline.  FGF-9 was eluted in Buffer B9 (50 mM Tris, 2 M NaCl, 1 mM DTT, pH 
7.5). The eluate was diluted 4-fold with 50 mM Tris and applied to a 1 mL HiTrap 
column (GE Healthcare UK Ltd, Buckinghamshire, UK), and eluted with an 
imidazole gradeint (50 mM to 500 mM imidazole) in 0.5 M NaCl, 1 mM DTT, 50 
mM Tris, pH7.5.  Eluted protein was dialysed against 10 mM phosphate, pH 7.5, 1 
mM DTT and then stored at -80°C. 
 
ELISA 
Maxisorp 96-well microtitre plates were coated with 3 µg/ml streptavidin (Pierce 
Biotechnology, IL, USA) in 0.1 M Na2CO3/0.1 M NaHCO3 (pH 9.6) for 16 h at 4°C 
and then blocked with 1% (w/v) BSA in PBS with 0.05% (v/v) Tween-20 (PBST). 
Porcine mucosal HS (PMHS) was internally biotinylated with EZ-link NHS-LC-
biotin (Pierce Biotechnology, IL, USA) as described previously [24] and plates coated 
with 100 µg/ml biotinylated PMHS for 2 h at room temperature and then washed with 
PBST. Fifteen µl of HS antibody was added to each well with 15 µl competitor FGF 
and incubated overnight at 4°C. Antibody dilutions were determined in a titre and 
were used at final concentrations of; HS3B7V 1/5, HS4E4V 1/2, HS3A8V 1/20, 
AO4B08V 1/5, EV3C3V 1/10 and EW4G1V 1/2. FGF2 (1.2 mg/ml) and FGF9 (2.2 
mg/ml) in sodium phosphate buffer, pH 7.4 were diluted in 1% (w/v) BSA in PBST to 
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the required concentrations. For a positive control, HS antibodies were added to wells 
alone, without FGF competitor and for a negative control, HS antibodies were added 
to wells lacking biotinylated HS. Plates were washed in PBST and bound HS antibody 
was detected with mouse anti-VSV-G IgG (clone P5D4) (Abcam, Cambridge, UK) 
diluted 1/2000 in 1% (w/v) BSA in PBST followed by HRP-conjugated sheep anti-
mouse IgG (GE Healthcare UK Ltd, Buckinghamshire, UK) diluted 1/2000 in 1% 
(w/v) BSA in PBST. After a final wash in PBST, plates were developed with o-
phenylenediamine (0.8 mg/mL) (AbD Serotec, Oxford, UK) containing 0.03% (v/v) 
hydrogen peroxide. The reaction was stopped with 0.5 M H2SO4 and absorbance read 
at 492 nm. 
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Figures 
Figure 1. HS ‘phage display antibodies identify distinct epitopes in situ. 
In fetal rat lungs, HS antibodies display different patterns of staining. HS3B7V 
exclusively labels epithelial basement membranes, whereas HS4E4V and HS3A8V 
show a more widespread staining pattern. In addition to epithelial basement 
membrane staining, HS4E4V labels sub-epithelial mesenchymal cells surrounding 
smaller distal airways and HS3A8V highlights the entire lung mesenchyme and in 
addition, stains epithelial cells at E15.5. One antibody, HS4C3V, did not stain fetal rat 
lungs of any developmental age; however, positive staining of adult rat kidney 
confirmed the functionality of HS4C3V in immunohistochemistry. 
E15.5 and E17.5 rat lungs and adult rat kidney were probed with HS antibodies 
followed by rabbit VSV-G tag antibody and FITC conjugated goat anti-rabbit IgG. 
Negative controls were omission of HS antibody or digestion of HS with heparitinase 
prior to antibody incubation (HS4E4V shown, heparitinase digest controls for other 
antibodies are shown in additional files). Scale bar represents 10 µm and all images 
are the same magnification. (ep) epithelium, (me) mesenchyme, (bm) basement 
membrane, (aw) airway, (G) glomerulus, (cap) peritubular capillary  
 
Figure 2. Different compartments of the lung display distinct HS epitopes e.g., 
airway epithelium. 
Airway epithelial cells display HS epitopes identified by EV3C3V, AO4B08V and 
HS3A8V. At E13.5, only the EV3C3V epitope is present and at E15.5, AO4B08V and 
HS3A8V epitopes are additionally displayed. HS structures recognised by HS3B7V, 
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HS4E4V and EW4G1V are not identified in the epithelium at any developmental 
stage. 
E13.5 and E15.5 rat lungs were probed with HS antibodies followed by rabbit VSV-G 
tag antibody and FITC conjugated goat anti-rabbit IgG. Scale bar represents 10 µm 
and all images are the same magnification. (ep) epithelium, (me) mesenchyme 
 
Figure 3. The spatial distribution of HS epitopes changes during mammalian 
lung morphogenesis. 
Antibody epitopes change in their pattern of distribution during the course of lung 
development. For example, the epitope recognised by HS3A8V is displayed 
exclusively by the epithelial basement membranes at E13.5, however, by E15.5, it is 
also present in the mesenchyme and on the surface of epithelial cells. At E17.5, the 
epitope is lost from the epithelium, and sub-epithelial mesenchymal expression is 
briefly increased, before becoming more widespread at E19.5 – E21.5. In contrast, the 
HS epitope recognised by EW4G1V is not present in E13.5 rat lungs and is only 
weakly expressed at E15.5 in epithelial basement membranes and mesenchyme 
surrounding smaller distal airways. Levels of this epitope increase considerably in 
epithelial basement membranes at E17.5, while mesenchymal expression remains 
relatively low and concentrated in sub-epithelial areas until E19.5 – E21.5, where 
epitope distribution becomes more widespread. 
E13.5 – E21.3 rat lungs were probed with HS antibodies followed by rabbit VSV-G 
tag antibody and FITC conjugated goat anti-rabbit IgG. Scale bar represents 10 µm 
and all images are the same magnification. (aw) airway, (bm) basement membrane, 
(me) mesenchyme, (ep) epithelium 
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Figure 4. HS epitope distribution in pulmonary vasculature. 
HS3B7V shows a unique pattern of vascular staining in fetal lungs, specifically 
highlighting the outer tunica media of arterial walls (arrow) and leaving the inner 
tunica media unlabelled. In addition, this antibody does not stain pulmonary veins. 
(Some weak, nuclear staining was observed with HS3B7V on occasion, including in 
veins. However, this was not sensitive to heparinase digestion and is therefore non-
specific staining). The remaining antibodies highlight the entire tunica media layer in 
the walls of both arteries and veins (only AO4B08V, HS4E4V and EV3C3V are 
shown, however, HS3A8V and HS4E4V display comparable blood vessel staining).  
Fetal rat lungs were probed with HS antibodies followed by rabbit VSV-G tag 
antibody and FITC conjugated goat anti-rabbit IgG. Scale bar represents 10 µm and 
all images are the same magnification. (A) artery, (V) vein, (aw) airway, (m) media 
  
Figure 5. HS structure is abnormal in hypoplastic nitrofen treated rat lungs. 
HSPG levels, identified by 3G10, are reduced in hypoplastic rat lungs, particularly at 
E15.5 and E17.5 and in epithelial basement membranes (A). Analysis of specific HS 
epitopes with ‘phage display antibodies revealed an abnormality in HS fine structure. 
A number of epitopes are reduced or lost from the epithelium e.g., AO4B08V and 
HS3A8V, respectively (B). In addition, a number of epitopes, e.g., HS4E4V, are 
reduced in the lung mesenchyme (C) and all epitopes are reduced in epithelial 
basement membranes (B, C). 
Hypoplastic lungs from rats with nitrofen-induced left sided CDH and control lungs 
from rats fed olive oil alone were probed with 3G10 after initial digestion of lung HS 
with heparitinase to reveal the 3G10 neo-epitope on all HSPGs. Bound antibody was 
then detected with FITC conjugated goat anti-mouse IgG. As a negative control, 
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sections were incubated with heparitinase buffer alone without enzyme, leaving the 
3G10 neo-epitope concealed. Incubation of lung sections with HS ‘phage display 
antibodies was followed by rabbit VSV-G tag antibody and FITC conjugated goat 
anti-rabbit IgG. Scale bars represent 10 µm. (ep) epithelium, (bm) basement 
membrane, (me) mesenchyme 
 
Figure 6. Spatiotemporal distribution of HS epitopes is abnormal in hypoplastic 
lungs. 
In normal development, a gradient of EV3C3V epitope distribution is observed in the 
mesenchyme of E15.5 – E17.5 lungs, with high epitope levels in sub-epithelial 
mesenchyme around distal airways (arrowhead) and lower levels around proximal 
airways. This organised gradient of EV3C3V epitope distribution is lost in lungs of 
nitrofen treated rats, which display the structure at a high level throughout the 
mesenchyme at E15.5 – E17.5. At E19.5 – E21.5, EV3C3V epitope levels and 
distribution are comparable to control lungs.  
Hypoplastic lungs from rats with nitrofen-induced left sided CDH and control lungs 
from rats fed olive oil alone were probed with EV3C3V followed by rabbit VSV-G 
tag antibody and FITC conjugated goat anti-rabbit IgG. Scale bar represents 10 µm 
and all images are the same magnification. (aw) airway, (me) mesenchyme 
 
Figure 7. Airway epithelial basement membranes are abnormal in hypoplastic 
lungs. 
Epithelial basement membranes appear thinner in nitrofen treated lungs, with reduced 
levels of HSPGs, identified by 3G10 antibody (A) and HS epitopes identified by 
‘phage display HS antibodies, e.g., HS4E4V and HS3B7V (B, C). Discontinuities in 
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basement membrane HS staining were also observed with HS antibody staining (B, C, 
arrowheads). This was not apparent with 3G10 immunohistochemistry, identifying all 
HSPGs (A). To visualise the general structure of basement membranes and assess 
whether the observed abnormalities are HS specific or a general defect in basement 
membrane structure, lungs were probed with an antibody to laminin (D). Staining 
with anti-laminin revealed thinner basement membranes, however, no discontinuities 
were observed.  
Hypoplastic lungs from rats with nitrofen-induced left sided CDH and control lungs 
from rats fed olive oil alone were probed with HS antibodies, 3G10 (after digestion of 
endogenous HS with heparitinase to reveal the 3G10 neo-epitope on all HSPGs) or 
anti-laminin antibody. Bound HS antibodies were detected with rabbit VSV-G tag 
antibody followed by FITC conjugated goat anti-rabbit IgG, 3G10 was detected with 
FITC conjugated goat anti-mouse IgG and anti-laminin was detected with FITC 
conjugated goat anti-rabbit IgG. Scale bars represent 10 µm. (aw) airway, (bm) 
basement membrane, (me) mesenchyme, (ep) epithelium 
 
Figure 8. Functional analysis of antibody epitope structures via competition 
ELISA with FGF2 and FGF9. 
FGF2 and FGF9 competed with a number of antibodies for HS binding, indicating 
that epitope structures are analogous to structures recognised by these growth factors. 
FGF2 competed for all six epitopes to variable extents, but most significantly with 
EV3C3V. FGF9, in contrast, showed more competitive selectivity and was only able 
to compete for two epitope structures, recognised by HS3B7V and HS3A8V. 
PMHS was biotinylated and immobilised on streptavidin coated microtitre plates. 
Equilibrium binding of HS antibodies in the presence of various concentrations of 
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FGF2 (A, B) or FGF9 (C, D) were quantified at A490 using an anti-VSV-G tag 
antibody (P5D4) followed by HRP conjugated anti-mouse antibody and OPD 
substrate. Absorbance values were converted to % inhibition of antibody binding to 
HS by FGFs and plotted against FGF concentration (A, C). Curves were generated 
using OriginPro and a non-linear logistic dose response fit. IC50 values (B, D) were 
calculated as the concentration of FGF required for 50% inhibition of antibody 
binding to immobilised HS. Values are the mean of triplicate samples, error bars 
represent the S.E and the data are representative of two separate experiments. 
* denotes antibody epitopes not competed for by FGF. 
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Additional files 
Additional file 1 – HS3B7V (PDF) 
Immunohistochemical staining of E13.5 – E21.5 normal lungs and E15.5 – E21.5 
hypoplastic lungs with HS3B7V.  
The HS3B7V HS epitope is localised to the epithelial basement membrane in both 
control and hypoplastic lungs from E15.5. However, in hypoplastic lungs, expression 
of this HS structure is reduced and staining of epithelial basement membranes is 
irregular. In addition, in nitrofen E19.5 lungs, there is additional weak staining 
identified in sub-epithelial mesenchyme. As a negative control, endogenous HS was 
digested with heparitinase prior to antibody incubation. 
(aw) airway, (mes) mesenchyme, (ep) epithelium, (bm) basement membrane, (br) 
bronchus 
 
Additional file 2 – HS4E4V (PDF) 
Immunohistochemical staining of E13.5 – E21.5 normal lungs and E15.5 – E21.5 
hypoplastic lungs with HS4E4V. 
In normal lungs, the HS4E4V HS epitope is present in epithelial basement membranes 
and the surrounding mesenchyme, particularly in sub-epithelial areas adjacent to 
distal airways. In hypoplastic lungs, expression of this epitope is severely reduced, 
particularly in epithelial basement membranes and mesenchyme of E15.5 and E17.5 
lungs. As a negative control, endogenous HS was digested with heparitinase prior to 
antibody incubation. 
(aw) airway, (oe) oesophagus, (mes) mesenchyme, (ep) epithelium, (bm) basement 
membrane, (br) bronchus 
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Additional file 3 – HS3A8V (PDF) 
Immunohistochemical staining of E13.5 – E21.5 normal lungs and E15.5 – E21.5 
hypoplastic lungs with HS3A8V. 
In normal lungs, the HS epitope recognised by HS3A8V is restricted to epithelial 
basement membranes at E13.5. From E15.5, distribution of the epitope is more 
widespread and is present in epithelial basement membranes and throughout the 
mesenchyme, particularly in sub-epithelial mesenchyme. Epithelial cells also display 
this HS structure transiently at E15.5 and (more weakly) at E17.5. In hypoplastic 
lungs, mesenchymal expression of the HS3A8V epitope is reduced, particularly at 
E15.5 and E17.5, and epithelial staining observed in normal lungs is lost. 
Additionally, irregularities in epithelial basement membrane staining are observed. As 
a negative control, endogenous HS was digested with heparitinase prior to antibody 
incubation. 
(aw) airway, (mes) mesenchyme, (ep) epithelium, (bm) basement membrane, (br) 
bronchus 
 
Additional file 4 – AO4B08V (PDF)  
Immunohistochemical staining of E13.5 – E21.5 normal lungs and E15.5 – E21.5 
hypoplastic lungs with AO4B08V.  
Expression of the AO4B08V HS epitope increases during the course of normal lung 
development. At E13.5, it is only weakly expressed by epithelial basement 
membranes, and at E15.5, is additionally displayed at a low level in the mesenchyme 
and airway epithelium. From E17.5 – E21.5, levels of this epitope increases in 
basement membranes and throughout the mesenchyme. In hypoplastic lungs, 
however, expression of the AO4B08V epitope is reduced in the epithelium and 
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underlying basement membranes, and in addition, basement membranes appear 
discontinuous. In lung mesenchyme, however, the AO4B08V epitope structure is 
displayed at a higher level compared to normal lungs. As a negative control, 
endogenous HS was digested with heparitinase prior to antibody incubation. 
(aw) airway, (mes) mesenchyme, (ep) epithelium, (bm) basement membrane, (br) 
bronchus 
 
Additional file 5 – EV3C3V (PDF) 
Immunohistochemical staining of E13.5 – E21.5 normal lungs and E15.5 – E21.5 
hypoplastic lungs with EV3C3V.  
In normal lungs, the EV3C3V epitope is displayed by the epithelium at E13.5 – E17.5 
and in the underlying basement membranes at E13.5 – E21.5. A gradient of epitope 
expression is observed in the mesenchyme, with highest levels in sub-epithelial 
mesenchyme around smaller, distal airways and lower levels in sub-mesothelial 
mesenchyme. However, in hypoplastic lungs, this gradient of mesenchymal 
expression is lost, and the EV3C3V epitope is more extensively and evenly 
distributed throughout the entire mesenchyme. In addition, epithelial staining is lost 
from hypoplastic lungs and basement membrane staining is irregular. As a negative 
control, endogenous HS was digested with heparitinase prior to antibody incubation. 
(aw) airway, (mes) mesenchyme, (ep) epithelium, (bm) basement membrane, (br) 
bronchus 
 
Additional file 6 – EW4G1V (PDF) 
Immunohistochemical staining of E13.5 – E21.5 normal lungs and E15.5 – E21.5 
hypoplastic lungs with EW4G1V. 
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In normal developing lungs, the HS structure identified by EW4G1V is absent at 
E13.5. From E15.5 onwards, however, it is present in all epithelial basement 
membranes and also at a low level in the mesenchyme, with increased levels at E21.5. 
This epitope is transiently expressed by the epithelium at E15.5. In hypoplastic lungs, 
levels of this epitope appear to be raised somewhat in the mesenchyme compared to 
normal lungs and simultaneously reduced in epithelial basement membranes. As a 
negative control, endogenous HS was digested with heparitinase prior to antibody 
incubation. 
(aw) airway, (mes) mesenchyme, (ep) epithelium, (bm) basement membrane, (br) 
bronchus 
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